Brief: UCB's BIMZELX achieves superiority to SKYRIZI in PsA head-to-head study

UCB SA

11/03/2026 07:58

March 11 (Reuters) - Ucb SA UCB.BR:

BIMZELX[®]▼(BIMEKIZUMAB) SUPERIOR TO SKYRIZI[®] (RISANKIZUMAB) IN BE BOLD: FIRST HEAD-TO-HEAD STUDY IN ACTIVE PSORIATIC ARTHRITIS (PSA) TO DEMONSTRATE SUPERIORITY IN ACR50

Source text: ID:nNDLbyXtPW

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))